Overview of the LiveWell Study
In less than a year, the LiveWell study has successfully recruited 996 participants from a single NHS site, utilizing real-world data from the NHS. This initiative is a collaboration between Predictive Health Intelligence (PHI) and Sano Genetics, with support from Somerset NHS Foundation Trust and Tawazun Health.
Key Highlights of the Recruitment Process
- Utilized hepatoSIGHT, a case-finding software, to identify individuals at higher risk of metabolic liver disease.
- Engaged participants through targeted mailings and screened them via the Sano Genetics platform.
- Enabled e-consent and at-home genetic testing, along with FibroScan appointment booking.
Recruitment Performance Metrics
The recruitment process showcased impressive engagement metrics:
- 1,300 unique visitors to the study landing page.
- 95% engagement rate.
- 76% conversion rate to sign-up.
- Over 99% of enrolled participants ordered a genetic test.
Importance of the Study
This milestone is significant as recruitment challenges often lead to delays in clinical trials. Approximately 80% of clinical trials fail to meet their recruitment targets, resulting in increased costs and delayed access to new therapies. The LiveWell study demonstrates that effective use of data and partnerships can enhance recruitment speed and participant engagement.
Patient Impact and Future Implications
For patients, this study represents a vital opportunity for early identification of liver and metabolic risks, potentially leading to timely interventions. Louise Campbell, a patient advocate, noted that the study has been life-changing for many participants.
Conclusion
The LiveWell study serves as a model for future research initiatives, showcasing how data-driven approaches can facilitate high-performance recruitment and improve health outcomes. The ongoing follow-up and assessments will continue to provide valuable insights into liver health risks.
About the Collaborating Organizations
- Predictive Health Intelligence: Focuses on early diagnosis of liver disease using historical data.
- Sano Genetics: Aims to simplify precision medicine studies through a comprehensive platform.
- Somerset NHS Foundation Trust: Provides a range of healthcare services and supports clinical research.
- Tawazun Health: Specializes in non-invasive liver assessments to identify disease risks.